Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing

McLeod, Allan; Weir, Alan; Aitken, Celia; Gunson, Rory; Templeton, Kate; Molyneaux, P.; McIntyre, P. G.; McDonald, Scott; Goldberg, David J.; Hutchinson, Sharon J.

doi:10.1136/jech-2014-204451

Cited by 63 publications

(52 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3. Updated systematic reviews and meta-analyses (based on 14 studies of DBS vs. venous blood specimens for HCV antibodies, and 7 studies for HCV RNA based on an update of one study to an existing review) also showed generally high diagnostic accuracy of DBS specimens for both serology and NAT, and good precision and France [200][201][202].…”

Section: Recommendations and Rationale For Use Of Dbs Samplingmentioning

confidence: 98%

Who to test and how to test for chronic hepatitis C infection – 2016 WHO testing guidance for low- and middle-income countries

Easterbrook

2016

Journal of Hepatology

111

View full text Add to dashboard Cite

Section: Recommendations and Rationale For Use Of Dbs Samplingmentioning

confidence: 98%

Who to test and how to test for chronic hepatitis C infection – 2016 WHO testing guidance for low- and middle-income countries

Easterbrook

2016

Journal of Hepatology

111

View full text Add to dashboard Cite

“…Screening programs using DBS have been running for several years in Great Britain, targeting in particular intravenous drug users. Up to 20% of new HCV diagnoses were made using DBS in 2013 in Scottish addiction treatment centers (McLeod et al, 2014). A program of this type has been implemented by the Montpellier teaching hospital since 2013 in all addiction treatment centers located in the Languedoc Roussillon Region (Accueillir, 2014).…”

Section: Indications Of Dbs In Infectious Diseasesmentioning

confidence: 99%

Dried Blood Spot Tests for the Diagnosis and Therapeutic Monitoring of HIV and Viral Hepatitis B and C

et al. 2020

View full text Add to dashboard Cite

Blood collected and dried on a paper card -dried blood spot (DBS) -knows a growing interest as a sampling method that can be performed outside care facilities by capillary puncture, and transported in a simple and safe manner by mail. The benefits of this method for blood collection and transport has recently led the World Health Organization to recommend DBS for HIV and hepatitis B and C diagnosis. The clinical utility of DBS sampling to improve diagnostics and care of HIV and hepatitis B and C infection in hard to reach populations, key populations and people living in low-income settings was highlighted. Literature about usefulness of DBS specimens in the therapeutic cascade of care -screening, confirmation, quantification of nucleic acids, and resistance genotyping -, was reviewed. DBS samples are suitable for testing antibodies, antigens, or nucleic acids using most laboratory methods. Good sensibility and specificity have been reported for infant HIV diagnosis and diagnosis of hepatitis B and C. The performance of HIV RNA testing on DBS to identified virological failure on antiretroviral therapy is also high but not optimal because of the dilution of dried blood in the elution buffer, reducing the analytical sensitivity, and because of the contamination by intracellular HIV DNA. Standardized protocols are needed for inter-laboratory comparisons, and manufacturers should pursue regulatory approval for in vitro diagnostics using DBS specimens. Despite these limitations, DBS sampling is a clinically relevant tool to improve access to infectious disease diagnosis worldwide.

show abstract

“…Potential strategies to improve HCV testing include education and counseling by health professionals with on-site HCV testing (Cullen et al, 2006; Lacey, Ellen, Devlin, Wright, & Mijch, 2007; Meyer et al, 2015; Rosenberg et al, 2010; Sahajian et al, 2011; Zhou et al, 2016), physical and electronic medical chart reminders to prompt targeted risk-based assessment and testing (Drainoni et al, 2012; Krauskopf et al, 2014; Litwin et al, 2012; Meyer et al, 2015; Zhou et al, 2016), and simplified testing, including dried blood spot testing (Abou-Saleh, Rice, & Foley, 2013; Coats & Dillon, 2015; Craine, O'Toole, D'Arcy, & Lyons, 2009; Hickman et al, 2008; McLeod et al, 2014; Meyer et al, 2015; Tait, Stephens, McIntyre, Evans, & Dillon, 2013; Zhou et al, 2016), and point-of-care HCV testing (Beckwith et al, 2016; Bottero et al, 2015; Morano et al, 2014). …”

Section: Hcv Testingmentioning

confidence: 99%

“…Although finger-stick dried blood spot testing enhances HCV testing (Abou-Saleh, et al, 2013; Coats & Dillon, 2015; Craine et al, 2009; Hickman et al, 2008; McLeod et al, 2014; Meyer et al, 2015; Tait et al, 2013; Zhou et al, 2016), collection cards need to be sent somewhere for testing at centralized diagnostic laboratories requiring people to come back for a second visit to receive their result. Among HIV-infected gay and bisexual men, innovative approaches using on-line ordering with self-collected dried blood spot testing simplifies testing and improves access to marginalized populations (Terrence Higgins Trust, 2016).…”

Section: Hcv Testingmentioning

confidence: 99%

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs

Grebely

Bruneau

Lazarus

et al. 2017

International Journal of Drug Policy

Self Cite

View full text Add to dashboard Cite

Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7. 5 million people who have recently injected drugs (PWID). There is an additional large, but unquantified, burden among those PWID who have ceased injecting. The incidence of HCV infection among current PWID also remains high in many settings. Morbidity and mortality due to liver disease among PWID with HCV infection continues to increase, despite the advent of well-tolerated, simple interferon-free direct-acting antiviral (DAA) HCV regimens with cure rates >95%. As a result of this important clinical breakthrough, there is potential to reverse the rising burden of advanced liver disease with increased treatment and strive for HCV elimination among PWID. Unfortunately, there are many gaps in knowledge that represent barriers to effective prevention and management of HCV among PWID. The Kirby Institute, UNSW Sydney and the International Network on Hepatitis in Substance Users (INHSU) established an expert round table panel to assess current research gaps and establish future research priorities for the prevention and management of HCV among PWID. This round table consisted of a one-day workshop held on 6 September, 2016, in Oslo, Norway, prior to the International Symposium on Hepatitis in Substance Users (INHSU 2016). International experts in drug and alcohol, infectious diseases, and hepatology were brought together to discuss the available scientific evidence, gaps in research, and develop research priorities. Topics for discussion included the epidemiology of injecting drug use, HCV, and HIV among PWID, HCV prevention, HCV testing, linkage to HCV care and treatment, DAA treatment for HCV infection, and reinfection following successful treatment. This paper highlights the outcomes of the roundtable discussion focused on future research priorities for enhancing HCV prevention, testing, linkage to care and DAA treatment for PWID as we strive for global elimination of HCV infection.

show abstract

Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing

Cited by 63 publications

References 23 publications

Who to test and how to test for chronic hepatitis C infection – 2016 WHO testing guidance for low- and middle-income countries

Who to test and how to test for chronic hepatitis C infection – 2016 WHO testing guidance for low- and middle-income countries

Dried Blood Spot Tests for the Diagnosis and Therapeutic Monitoring of HIV and Viral Hepatitis B and C

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs

Contact Info

Product

Resources

About